Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test spot eye damage from diabetes?

NCT ID NCT05079399

Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study aims to find a blood marker that can tell how healthy the blood vessels in the eye are for people with diabetic retinopathy. Researchers will collect blood samples from 192 participants with type 2 diabetes and analyze special cells in the blood. The goal is to discover a way to monitor the condition without relying only on eye exams.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to monitor diabetic retinopathy and guide treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. It may not find a reliable marker, and any future test would need much more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We will recruit type 2 diabetes individuals with different severities of diabetic retinopathy and non-diabetes controls.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to cooperate with imaging procedures. * Health status: established type 2 diabetes * No history of panretinal photocoagulation (PRP) * No history of treatment with intravitreal agents for past 12 months Exclusion Criteria: * Previous or current malignancy * Acute or chronic infection (HIV, hepatitis B or C, tuberculosis) * Cerebral vascular accident or cerebral vascular procedure * Current pregnancy * History of organ transplantation * Presence of a graft (to avoid any effect of the graft) * History of previous vitrectomy * Subjects with a history of age-related macular degeneration age-related macular degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eskenazi Eye Clinic

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Glick Eye Institute

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Spring Mill Clinic

    RECRUITING

    Carmel, Indiana, 46920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.